Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Trikafta in Cystic Fibrosis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03506061
Recruitment Status : Recruiting
First Posted : April 23, 2018
Last Update Posted : March 25, 2020
Sponsor:
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Eric Sorscher, MD, Emory University

Brief Summary:
Cystic Fibrosis (CF) is a life threatening genetic disorder resulting from mutations found in the gene known as the cystic fibrosis transmembrane conductance regulator (CFTR). This clinical study will enroll 22 participants without the F508del mutation, carrying partial function mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the immediate future. Each participant will be given Trikafta for approximately four weeks. The study researchers will monitor clinical endpoints that include forced expiratory volume (FEV1), sweat chloride, and nasal potential difference. Additionally, the researchers will obtain skin biopsy material from each subject so that induced pluripotent stem (iPS) cells can be modified into airway cell monolayers and tested for response to Trikafta. In this way, the study will evaluate an emerging and readily accessible in vitro endpoint as a predictor of clinical response. This study will serve as a pilot/test case for other clinical protocols relevant to patients with rare CFTR variants who do not currently receive modulator therapies. It is hypothesized that a robust correlation will be established between in vitro Trikafta responsiveness of iPS cells and in vivo benefit (FEV1) to patients, and will provide a new tool for utilizing iPS to identify patient populations most suitable for cystic fibrosis modulator therapy.

Condition or disease Intervention/treatment Phase
Cystic Fibrosis Drug: Trikafta Phase 2

Detailed Description:

Cystic Fibrosis (CF) is a life threatening genetic disorder resulting from mutations found in the gene known as the cystic fibrosis transmembrane conductance regulator (CFTR). Defects in this gene prevent correct chloride transport in and out of cells. It has become increasingly important to develop new in vitro model systems capable of predicting in vivo clinical effectiveness of modulator therapy among patients with CF. This objective represents a significant and unmet need for advancing personalized therapeutics in the disease. The current trial is intended to show for the first time that primary iPS cells differentiated to an airway epithelial phenotype can be used to predict in vivo clinical response for rare CF patient populations - with the long-term goal of facilitating drug access for individuals with unusual (or even private) CF variants.

Trikafta is currently approved for patients with CF carrying at least one copy of the common F508del variant. This study is a clinical study of 22 subjects without the F508del mutation, carrying partial function mutations not approved for Trikafta, and who are not expected to be approved for CFTR modulator treatment in the immediate future.

Each participant will have clinical and/or preclinical evidence that Trikafta should offer benefit, and each will be given Trikafta for approximately four weeks. The researchers will monitor clinical endpoints that include FEV1, sweat chloride, and nasal potential difference. The study will differentiate iPS cells from each subject to generate airway epithelial monolayers that can be tested for response to Trikafta. In this way, this study will evaluate an emerging and readily accessible in vitro surrogate endpoint as a predictor of clinical response. This trial will also serve as a pilot/test case for other clinical protocols relevant to patients with rare CFTR variants and evidence of residual function who do not have an approved modulator therapy-due to rarity of their mutation. It is hypothesized that a robust correlation will be established between in vitro Trikafta responsiveness of iPS cells and in vivo benefit (FEV1) in patients, and provide a powerful tool for utilizing iPS cells to identify rare CF patient populations most suitable for cystic fibrosis modulator therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: iPS Cell Response to CFTR Modulators: Study of Trikafta in CF Patients Carrying Partial Function Mutations
Actual Study Start Date : September 4, 2019
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cystic Fibrosis
Drug Information available for: Ivacaftor

Arm Intervention/treatment
Experimental: Trikafta
Participants will receive Trikafta for 28 days
Drug: Trikafta
Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (taken in the morning), and 150 mg of ivacaftor taken in the evening.
Other Names:
  • ivacaftor
  • tezacaftor
  • elexacaftor




Primary Outcome Measures :
  1. Change in forced expiratory volume in one second (FEV1) [ Time Frame: Baseline, Days 7, 14, 28, 56 ]
    FEV1 provides a direct measurement of patient health among individuals with cystic fibrosis and declines in FEV1 are associated with poor outcomes among those with CF. FEV1 is measured by spirometry and is the maximum amount of air the participant can blow out in one second.

  2. Response of iPS cells to treatment [ Time Frame: Baseline ]
    Cutaneous punch biopsy material will be collected from each participant so that iPS cells can be differentiated into airway epithelial monolayers and tested for response to the treatment, in vitro. By using iPS cells differentiated to exhibit a respiratory epithelial phenotype, this study will determine whether the cells can be used to predict clinical responsiveness to Trikafta.


Secondary Outcome Measures :
  1. Change in sweat chloride [ Time Frame: Baseline, Days 14, 28, 56 ]
    Persons with CF have higher levels of chloride in their sweat. Sweat chloride concentrations of less than or equal to 29 mmol/L are considered normal, concentrations of 30-59 mmol/L are considered intermediate and indicate that the individual may have CF. Concentrations of 60 mmol/L and more mean that a diagnosis of CF is likely.

  2. Change in nasal potential difference (NPD) measurements [ Time Frame: Baseline, Days 7, 14, 28, 56 ]
    Nasal potential difference assesses the function of CFTR protein by measuring the electrical response of nasal mucosa to the perfusion of different ionic solutions. The nasal potential difference test uses a small needle placed under the skin of the arm a few inches above the wrist. A very thin piece of tubing is placed into the nose, through which ionic solutions are pumped. Response to each solution is recorded by an electrode feeding into a microvolt meter.

  3. Change in Cystic Fibrosis Questionnaire - Revised (CFQ-R) Score [ Time Frame: Baseline, Days 14, 28, 56 ]
    Participants will take the CFQ-R that corresponds to their age to assess quality of life. Responses to questions are coded as 1 = very true or always, 2 = mostly true or often, 3 = somewhat true or sometimes, and 4 = not at all true or never. Some items are reverse scored so that higher scores indicate increased ability and higher quality of life. For this study, a summary score will be calculated to provide a single quality of life value. The questionnaire for ages 12-13 includes 35 questions and total scores can range from 35 to 140. The questionnaire for ages 14 and older has 50 questions and total scores range from 50 to 200.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of signed and dated informed consent form or assent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female age ≥12
  • A clinical diagnosis of CF or CFTR-related disease and evidence for a partial function mutation not currently covered or likely to be covered for FDA treatment with a CFTR modulator

    • A diagnosis of CF as defined by current guidelines: one or more clinical features consistent with the CF phenotype or positive CF newborn screen AND one or more of the following criteria: sweat chloride ≥ 60 mmol/L by quantitative pilocarpine iontophoresis or 2 well characterized disease-causing CFTR gene mutations
    • Or, with the consensus of two study co-investigator physicians, a clinical diagnosis of CF or CFTR-related disorder with documented evidence of chronic pulmonary disease (chronic cough with sputum production, persistent pulmonary radiographic abnormalities (e.g bronchiectasis), chronic abnormality in percent predicted FEV1 (ppFEV1), and/or persistent colonization with a typical CF pathogen)
  • Sweat Chloride < 80 mmol/L and/or pancreatic sufficiency as indicated by no exogenous pancreatic enzyme supplement therapy
  • FEV1% predicted ≤ 90 Pre Bronchodilator using equations of the Global Lung Function Initiative (GLI) and meeting American Thoracic Society (ATS) criteria for acceptability and repeatability
  • Clinically stable in the past 4 weeks with no evidence of CF exacerbation
  • Willingness to use at least one form of acceptable birth control including abstinence or condom with spermicide. This will include birth control for at least one month prior to screening and agreement to use such a method during study participation for an additional four weeks after the last administration of study drug.
  • Ability to take Trikafta
  • Agreement to adhere to all current medical therapies as designated by the CF care center physician

Exclusion Criteria:

  • Documented history of drug or alcohol abuse within the last year
  • Subjects should not have a pulmonary exacerbation or changes in therapy for pulmonary disease in the 4 weeks prior to screening
  • Listed for lung or liver transplant at the time of screening
  • Cirrhosis or elevated liver transaminases > 3 times the upper limit of normal
  • Pregnant or breastfeeding
  • Inhibitors or inducers of CYP3A4, including certain herbal medications and grapefruit/grapefruit juice, or other medicines known to negatively influence Trikafta administration
  • History of solid organ transplant
  • History of non-tuberculous mycobacterial infection (any positive culture in the past 18 months) or active therapy for these infections
  • Known allergy to Trikafta
  • Treatment in the last 6 months with either Kalydeko, Orkambi or Symdeko
  • Any other condition that in the opinion of the lead investigators might confound results of the study or pose an additional risk from administering study drug
  • Treatment with another investigational drug or other intervention within one month prior to enrollment, throughout the duration of study participation, and for an additional four weeks following final drug administration
  • Evidence of cataract/lens opacity determined to be clinically significant by an ophthalmologist at or within 3 months prior to the Screening Visit

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03506061


Contacts
Layout table for location contacts
Contact: Eric Sorscher, MD 205-612-1327 esorscher@emory.edu

Locations
Layout table for location information
United States, Alabama
University of Alabama Cystic Fibrosis Research Center Recruiting
Birmingham, Alabama, United States, 35233
Contact: George Soloman, MD    205-975-9776    msolomon@uab.edu   
United States, Georgia
Emory Children's Center Recruiting
Atlanta, Georgia, United States, 30322
Contact: Eric Sorscher, MD    205-612-1327    esorscher@emory.edu   
Sponsors and Collaborators
Emory University
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Eric Sorscher, MD Emory University
Layout table for additonal information
Responsible Party: Eric Sorscher, MD, Professor, Emory University
ClinicalTrials.gov Identifier: NCT03506061    
Other Study ID Numbers: IRB00108656
300001205 ( Other Identifier: University of Alabama )
R01HL139876 ( U.S. NIH Grant/Contract )
First Posted: April 23, 2018    Key Record Dates
Last Update Posted: March 25, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cystic Fibrosis
Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Ivacaftor
Chloride Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action